Procaspase combination therapy for glioblastoma

Patent metadata

Field	Value
Publication number	US-10874666-B2
Application number	US-201816148344-A
Country	US
Kind code	B2
Filing date	Oct 1, 2018
Priority date	Mar 6, 2012
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.

First claim

What is claimed is:

1. A method of treating cancer in a subject in need thereof comprising administering to a subject in need of therapy for cancer, concurrently or sequentially, a therapeutically effective amount of a compound of Formula (I):

and a therapeutically effective amount of the compound PAC-1:

wherein the concentration of the compound of Formula I is about 250 μM to about 750 μM or about 50 mg/kg, and the concentration of PAC-1 is about 5 μM to about 30 μM or about 50 mg/kg, the cancer is glioblastoma multiforme (GBM) or meningioma and the cancer is thereby treated.

2. The method of claim 1 wherein the cancer is glioblastoma multiforme.

3. The method of claim 1 wherein the cancer is meningioma.

4. The method of claim 1 wherein the concentration of PAC-1 is 5 μM to 30 μM.

5. The method of claim 1 wherein the concentration of the compound of Formula I is about 250 μM, about 500 μM, or about 750 μM.

6. The method of claim 4 wherein the concentration of the compound of Formula I is 250 μM to 750 μM.

7. The method of claim 5 wherein the concentration of PAC-1 is 5 μM, about 10 μM, about 12.5 μM, about 25 μM, or 30 μM.

8. The method of claim 1 wherein the compound of Formula (I) and the compound PAC-1 are administered by infusion, by injection, by oral administration, or a combination thereof.

9. The method of claim 1 wherein the compound of Formula (I) and the compound PAC-1 are administered concurrently.

10. The method of claim 1 wherein the compound of Formula (I) and the compound PAC-1 are administered sequentially, wherein the compound of Formula (I) is administered before the compound PAC-1, or the compound of Formula (I) is administered after the compound PAC-1.

11. The method of claim 1 wherein the concentration of the compound of Formula I with respect to the concentration of PAC-1 is synergistic.

12. The method of claim 1 wherein the concentration of the compound of Formula I and the concentration of PAC-1 are synergistic.

Assignees

• Univ Illinois
• Vanquish Oncology Inc
• Univ Johns Hopkins

Inventors

• Hergenrother Paul J
• Botham Rachel C
• Fan Timothy M
• Gilbert Mark J
• Handley Michael K
• Joshi Avadhut
• Riggins Gregory J
• Tarasow Theodore M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K9/4858

  Organic compounds · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title